{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T19:57:47Z","timestamp":1769371067284,"version":"3.49.0"},"reference-count":0,"publisher":"Tunisian Society of Medical Sciences","issue":"11","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tunis Med"],"abstract":"<jats:p>Introduction: L\u2019allogreffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques (allo-CSH) est indiqu\u00e9e dans Les leuc\u00e9mies aigues my\u00e9loblastiques (LAM) de l\u2019enfant \u00e0 haut risque (HR).\nObjectif: Evaluer la survie globale(SG) , survie sans \u00e9v\u00e9nement(SSE),la rechute et la mortalit\u00e9 non li\u00e9e \u00e0 la rechute (NRM).\nM\u00e9thodes: Etude descriptive r\u00e9trospective, ayant inclus les enfants (\u02c218ans) atteints de LAM allogreff\u00e9s \u00e0 partir d\u2019un donneur g\u00e9no-identique entre1999 et2023. Le conditionnement pr\u00e9-greffe \u00e9tait de type Busulfan-cyclophosphamide(BuCy)ou irradiation corporelle totale-Cy. Le greffon \u00e9tait de type moelle osseuse(MO)ou cellules souches p\u00e9riph\u00e9riques.\nR\u00e9sultats: Cinquante-deux enfants ont \u00e9t\u00e9 inclus avec un \u00e2ge m\u00e9dian de 13ans (3-17ans).Les patients \u00e9taient Class\u00e9s HR dans 60,3% des cas. Le d\u00e9lai m\u00e9dian diagnostic-greffe \u00e9tait de 5 mois (3-40mois). En pr\u00e9-greffe,75% des patients \u00e9taient en RC1. Le greffon \u00e9tait de \u00a0type MO dans 84,6% des cas. Le conditionnement \u00e9tait de type BuCy dans 90,4% des cas. Le taux de rejet \u00e9tait de 5,8%. Les incidences cumul\u00e9es (IC) de la GVHD aigue et de la GVHD chronique \u00e9taient de 20% et de 23,4%, respectivement. L\u2019IC de la NRM \u00e9tait de7,7% et de la rechute \u00e9tait de 44,7%. Apr\u00e8s un suivi m\u00e9dian de 30mois (39j-18ans),l aSG et la SSE \u00e0 3 ans \u00e9taient de 51,6%et47,8%, respectivement.\nConclusion: La rechute postallo-CSH demeure un probl\u00e8me majeur.Le renforcement du Conditionnement pr\u00e9-greffe, l\u2019\u00e9tude de la pharmacocin\u00e9tique du Bu et le d\u00e9veloppement des\nTh\u00e9rapies cibl\u00e9es pourraient r\u00e9duirece risque<\/jats:p>","DOI":"10.62438\/tunismed.v103i11.5353","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T14:08:24Z","timestamp":1769090904000},"source":"Crossref","is-referenced-by-count":0,"title":["Allogreffe decellules souches h\u00e9matopo\u00ef\u00e9tiques dans les leuc\u00e9mies aigues my\u00e9loblastiques de l\u2019enfant: Survieet rechute"],"prefix":"10.62438","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9529-4192","authenticated-orcid":false,"given":"Nour","family":"Ben Abdeljelil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Insaf","family":"Ben Yaiche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rihab","family":"Ouerghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ines","family":"Turki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lamia","family":"Torjemane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorra","family":"Belloumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrine","family":"Mekni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rimel","family":"Kanoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Chabaane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saloua","family":"Ladeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek","family":"Ben Othman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"31112","published-online":{"date-parts":[[2026,1,22]]},"container-title":["La Tunisie M\u00e9dicale"],"original-title":[],"deposited":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T14:07:08Z","timestamp":1769350028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.latunisiemedicale.com\/index.php\/tunismed\/article\/view\/5353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":0,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,1,22]]}},"URL":"https:\/\/doi.org\/10.62438\/tunismed.v103i11.5353","relation":{},"ISSN":["2724-7031","0041-4131"],"issn-type":[{"value":"2724-7031","type":"electronic"},{"value":"0041-4131","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,22]]}}}